EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma

Roberto Silvestri, Margherita Piccardi iD, Alessia Laurenza, Filomena Rea, Allison R Sirois, Martina Lari, Francesco Bartoli, Giovanni Signore iD, Lorena Tedeschi iD, Elisabetta Ferraro, Paola Anna Erba, Roberto Giovannoni und 3 weitere

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Roberto Silvestri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Pisa, Pisa 56126, Italy. Hauptthemen laut MEDLINE: Mesothelioma, GPI-Linked Proteins, Protein Engineering, Pleural Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Ministero dell?Istruzione, dell?Universit? e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesothelin (MSLN) is a tumor biomarker expressed at high levels on the surface of numerous cancers with extremely limited expression in healthy tissues. MSLN-targeting agents developed for diagnosis and therapy could have a significant impact on the management of MSLN-expressing cancers. Pleural mesothelioma (PM) is a deadly cancer that arises from mesothelial cells lining the pleura and is predominantly linked to asbestos exposure. There are currently no effective treatments, and diagnosis occurs in late stages of disease due to the lack of clinical symptoms in the early stages. Recent efforts to diagnose and treat PM have focused on identifying and targeting relevant biomarkers, including MSLN. We engineered proteins based on the nonantibody fibronectin type III (Fn3) protein scaffold that bind MSLN with high affinity and specificity, using yeast-surface display and directed evolution. Previous work with Fn3 scaffold proteins has demonstrated tissue distribution desirable for applications in molecular imaging and targeted radiotherapy, which may overcome limitations encountered thus far with antibody-based approaches to treat PM. The MSLN-targeting Fn3 was further developed for bioconjugation with the 1,4,7,10-tetraazacyclododecane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) radiometal chelator. MSLN-binding Fn3 specifically binds to the MSLN-expressing PM lines, colocalizes with MSLN, and internalizes upon binding. Fn3-DOTAGA was further coupled with cold metal gallium-69, and the resulting conjugate maintained binding with high affinity to MSLN-expressing PM cells. MSLN-binding Fn3-DOTAGA-69Ga is a promising molecule with diagnostic and therapeutic relevance, toward applications in molecular imaging and targeted radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesotheliomaGPI-Linked ProteinsProtein EngineeringPleural NeoplasmsTheranostic NanomedicineFibronectinsMesothelinHumansCell Line, TumorProtein Binding

Substanzen

MesothelinMSLN protein, humanGPI-Linked ProteinsFibronectins

Autor:innen und Institutionen

  • Department of Biology, University of Pisa, Pisa 56126, Italy.
  • Picker Engineering Program, Smith College, Northampton, Massachusetts 01063, United States.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa 56126, Italy.
  • Molecular and Cellular Biology Program, University of Massachusetts Amherst, Amherst, Massachusetts 01003, United States.
  • Institute of Clinical Physiology, CNR, Pisa 56124, Italy.
  • School of Medicine and Surgery, University of Milan Bicocca, Milan 20126, Italy.

ORCID-Profile: Margherita Piccardi, Giovanni Signore, Lorena Tedeschi, Sarah J Moore

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Ministero dell?Istruzione, dell?Universit? e della Ricerca
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Silvestri, R., Piccardi, M., Laurenza, A., Rea, F., Sirois, A. R., Lari, M., Bartoli, F., Signore, G., Tedeschi, L., Ferraro, E., Erba, P. A., Giovannoni, R., Landi, S., Gemignani, F., & Moore, S. J. (2025). Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00425

Vancouver

Silvestri R, Piccardi M, Laurenza A, Rea F, Sirois AR, Lari M, et al. Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00425

BibTeX
@article{Silvestri2025,
  author = {Silvestri, Roberto and Piccardi, Margherita and Laurenza, Alessia and Rea, Filomena and Sirois, Allison R and Lari, Martina and Bartoli, Francesco and Signore, Giovanni and Tedeschi, Lorena and Ferraro, Elisabetta and Erba, Paola Anna and Giovannoni, Roberto and Landi, Stefano and Gemignani, Federica and Moore, Sarah J},
  title = {Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00425}
}
Kostenlos starten →